Abstract: The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
September 7, 2021
Assignee:
GE HEALTHCARE AS
Inventors:
Andreas Richard Meijer, Mikkel Jacob Thaning, Paritosh Jayant Dhawale, Salvatore Desena, Paul Alexander Jones, Deirdre Cassidy, Concetta Valeria Gringeri
Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
September 7, 2021
Assignee:
GENERAL ELECTRIC COMPANY
Inventors:
Brian Christopher Bales, Michael James Rishel
Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
Type:
Grant
Filed:
August 28, 2015
Date of Patent:
August 31, 2021
Assignee:
CHDI Foundation, Inc.
Inventors:
Celia Dominguez, John Wityak, Jonathan Bard, Alex Kiselyov, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Daniel Clark-Frew
Abstract: A method for producing a solution including a positron emitting zinc cation of 63Zn, and the method comprises bombarding a solution target including 63Cu with high energy protons to produce a solution including a positron emitting zinc cation. A method for detecting or ruling out Alzheimer's disease in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to ?-amyloid in the patient, and acquiring an image to detect the presence or absence of ?-amyloid in the patient. A method for detecting or ruling out cancer in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to tissue in the patient; and acquiring an image using a medical imaging technique to detect zinc distribution in tissue in the patient.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
August 31, 2021
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Timothy R. Degrado, Mukesh K. Pandey, Hendrik Petrus Engelbrecht, Val J. Lowe
Abstract: The present invention relates to 18F-labeled compounds suitable for positron emission tomography (PET) imaging. The invention further relates to the use of these compounds for carrying out PET scans, imaging the indoleamine 2,3-dioxygenase, pathway, predicting the responsiveness of a subject with a solid tumor to therapies including immunotherapy such as PD-1/PD-L1 inhibition, and determining whether a solid tumor in a subject contains tumor-infiltrating immune cells.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
August 31, 2021
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Zibo Li, Zhanhong Wu, Ben Giglio, Stergios Moschos
Abstract: Disclosed is a lymph targeting nuclear magnetic contrast agent using a brown algae polysaccharide as a carrier, and a preparation method and a use thereof. A macromolecular contrast agent with good water solubility was prepared by using the brown algae polysaccharide as the carrier, using mannose or mannose derivatives as a mannose receptor (MBP) recognition group, and using a paramagnetic metal ion chelate as a nuclear magnetic resonance imaging group. The binding capacity of lymphoid tissue was improved. The mannose or mannose derivative group introduced into the synthesized contrast agent molecule achieves the goal of binding to the enriched mannose receptors in the lymphoid tissues. At the same time, after the contrast agent is injected subcutaneously, both lymph vessels and lymph nodes were clearly visualized under MRI scanning.
Type:
Grant
Filed:
August 18, 2016
Date of Patent:
August 31, 2021
Assignee:
OCEAN UNIVERSITY OF CHINA
Inventors:
Tao Jiang, Shengbiao Wan, Wei Shang, Nan Zhang, Mingliang Zhao
Abstract: A method of labelling biological molecules with 18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.
Type:
Grant
Filed:
May 2, 2014
Date of Patent:
August 31, 2021
Assignees:
GE HEALTHCARE UK LIMITED, University of Southampton
Inventors:
Rajiv Bhalla, Gill Reid, William Levason
Abstract: The disclosure relates to a method for providing original data that can be used for subsequently determining the function of an organ of a living organism or for subsequently diagnosing a disease or a severity of a disease of an organ of a living organism. This method is characterized by several steps, one of which is administering a marker substance to a living organism by inhalation, wherein the marker substance has a vapor pressure above 0.01 mmHg at 37° C. In other method steps, the concentration of this marker substance in exhaled air is determined at at least two different time points. Then, a difference in marker substance concentration is calculated.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
August 31, 2021
Assignee:
FREIE UNIVERSITÄT BERLIN
Inventors:
Theodore Von Haimberger, Anja Heyne, Karsten Heyne
Abstract: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of therapeutic agents. In one embodiment, these compositions are used for the tumor-targeted delivery of chemotherapeutic agents useful for treating cancer.
Abstract: Provided herein are compounds for the imaging and treatment of TDP43-mediated disorders. The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
August 24, 2021
Assignee:
Washington University
Inventors:
Vijay Sharma, Jothilingam Sivapackiam, Sundaram S. M. Guruswami
Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.
Type:
Grant
Filed:
January 14, 2019
Date of Patent:
August 24, 2021
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Christian Preihs, Jing Yu, Veronica Clavijo Jordan, Yunkou Wu, Khaled Nasr, A. Dean Sherry, Sara Chirayil
Abstract: Disclosed are: an intermediate capable of high-purity synthesis of gadobutrol which can be used as an MRI contrast agent; and a gadobutrol production method using same. The gadobutrol intermediate is represented by Chemical Formula 2 in the specification.
Type:
Grant
Filed:
August 29, 2018
Date of Patent:
August 17, 2021
Assignee:
ENZYCHEM LIFESCIENCES CORPORATION
Inventors:
Jae Young Lee, Jong Soo Lee, Byung Kyu Kang, Sang Oh Lee, Byouong Woo Lee, Dae Myoung Yun, Jae Hun Bang, Choi Kyung Seok
Abstract: A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
August 17, 2021
Assignee:
SeeCure Taiwan Co., Ltd.
Inventors:
Tsung-Tien Kuo, David J. Yang, Wei-Chung Chang, Min-Ching Chung, Chi-Shiang Ke
Abstract: The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this system. The present invention provides advantages over known methods for evaporation of a radioactive fluid as it reduces drastically the amount of radioactive gaseous chemicals that are released in the hot cell. It is gentler and more secure compared to the known process and provides access to radiosyntheic processes that may not been acceptable for safety reasons related to release of volatile radioactive gases during evaporation. In addition, the process yields are higher because the radioactive volatiles are labelled intermediate species.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
August 17, 2021
Assignee:
GE HEALTHCARE LIMITED
Inventors:
Xavier Franci, Steve Lignon, Audrey Lange
Abstract: A lipid-, polymer-, and metal-based system of modified nanostructures of active biomedical and pharmaceutical agents used for in vivo (whole body/organ or tissue-specific) imaging. The modified nanostructure system involves various combinations of excipients (lipids, oils, surfactant, polymers, metals, carbon, nanotubes, etc.) in a formulation that allows a user to: (1) sustain the bioluminescent, fluorescent, or contrast signal for a longer period than conventional systems without repetitive administration (e.g., nanostructure system of luciferin), (2) target specific sites of interest (e.g., organ, tissue, receptors, proteins, etc.) for enhanced imaging of the targeted site (e.g. nanostructure system of XenoLight DIR with CREKA allows imaging of tumor vasculature), and (3) increase bioluminescent, fluorescent, or contrast signal flux.
Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.
Abstract: The present invention provides a composition comprising anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid (18F-FACBC) having an improved impurity profile compared with previous such compositions. Also provided is a method to obtain said composition.
Type:
Grant
Filed:
June 30, 2015
Date of Patent:
August 3, 2021
Assignee:
GE HEALTHCARE LIMITED
Inventors:
Knut Richard Dyrstad, Torild Wickstrom, Thanushan Rajanayagam